Top

Drug Safety

Published in:

01-08-2006 | Original Research Article

Clinical Risk Management in Dutch Community Pharmacies

The Case of Drug-Drug Interactions

Authors: Henk Buurma, Peter A.G.M De Smet, Antoine C.G. Egberts

Published in: Drug Safety | Issue 8/2006

Abstract

Background: The prevention of drug-drug interactions requires a systematic approach for which the concept of clinical risk management can be used. The objective of our study was to measure the frequency, nature and management of drug-drug interaction alerts as these occur in daily practice of Dutch community pharmacies.

Methods: In total, 63 Dutch pharmacies collected all drug-drug interaction alerts during 153 research days (on average 2.4 days/pharmacy), as well as variables related to these alerts, such as involved medicines, first time or recurrent drug-drug interaction, same or different prescribers, patient data (age, sex) and information about the management of drug-drug interactions by the pharmacy. The latter was discriminated into internal procedures only and external action, such as communication with the patient, the prescriber or the anticoagulation clinic and prescription modification. All drug-drug interactions were classified into categories of clinical relevance (A–F) and available evidence (0–4).

Results: A total of 43 129 prescription-only medicines were dispensed during the study period. On average, 16.8 interaction alerts per day per pharmacy were collected. Approximately 6% of all prescriptions generated a drug-drug interaction alert. Of all alerts (n = 2572), 31.1% occurred for the first time and with 21% two different prescribers were involved. The 20 most frequently occurring drug-drug interaction alerts accounted for approximately 76% of all alerts. Cardiovascular drugs, NSAIDs, oral contraceptives and antibacterials were most frequently involved. External action was taken in response to 27.3% of the alerts, meaning either a modification of one of the concerned prescriptions (n = 65; 9.3%), communication with the prescriber or anticoagulation clinic (n = 90; 12.8%) or communication with the patient or a relative (n = 547; 77.9%). Where there was no external action (n = 1860; 72.3%), pharmacists concluded in about two-thirds of cases that the drug-drug interaction had been managed in the past. Other reasons not to intervene externally were for instance: incorrect alert; acceptable drug-drug interaction; or outcome of the interaction considered irrelevant. Adjusted for several variables, a first alert was found to be a main determinant for external action. After stratifying for first alerts no other significant determinants were found.

Conclusions: A high frequency of drug-drug interaction alerts was found. Most concerned recurrent alerts, which were the main reason not to act externally. Concerning the assessment phase in the risk-management process, drug-drug interactions with no or low evidence/relevance should be reconsidered. Concerning the management of drug-drug interactions in pharmacies, the opportunity to actively suppress alerts for a certain period of time should be studied in more detail. There are indicators that the management of patient-orientated advice could be improved and a greater degree of consistency developed for the management of first and recurrent interaction alerts.

All drug-drug interaction alerts found in this study are presented on our website http://www.stevenshof.nl.

Misson JC. A review of clinical risk management. J Qual Clin Pract 2001; 21(4): 131–4PubMedCrossRef

Madar J. Clinical risk management in newborn and neonatal resuscitation. Semin Fetal Neonatal Med 2005; 10(1): 45–61PubMedCrossRef

Guideline on risk management systems for medicinal products for human use. London: European Medicines Evaluation Agency, 2005 Sep 6

Buurma H, de Smet PA, van den Hoff OP, et al. Nature, frequency and determinants of prescription modifications in Dutch community pharmacies. Br J Clin Pharmacol 2001; 52(1): 85–91PubMedCrossRef

Sandars J, Esmail A. The frequency and nature of medical error in primary care: understanding the diversity across studies. Fam Pract 2003; 20(3): 231–6PubMedCrossRef

Kohn LT, Corrigan CJ, Donaldson MS, editors. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999

Westerlund LT, Marklund BR, Handl WH, et al. Nonprescription drug-related problems and pharmacy interventions. Ann Pharmacother 2001; 35(11): 1343–9PubMedCrossRef

Boyko Jr WL, Yurkowski PJ, Ivey MF, et al. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health Syst Pharm 1997; 54(14): 1591–5PubMed

Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther 2002; 27(2): 107–10PubMedCrossRef

10.

Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev 2000; (3): CD000336

11.

Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother 1999; 33(12): 1336–55PubMedCrossRef

12.

Tully MP, Seston EM. Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. Ann Pharmacother 2000; 34(11): 1320–31PubMedCrossRef

13.

Buurma H, De Smet PA, Leufkens HG, et al. Evaluation of the clinical value of pharmacists’ modifications of prescription errors. Br J Clin Pharmacol 2004; 58(5): 503–11PubMedCrossRef

14.

Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9(1): 51–9PubMedCrossRef

15.

Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63PubMedCrossRef

16.

Bouvy ML, Heerdink ER, Hoes AW, et al. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26(13): 983–9PubMedCrossRef

17.

Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289(13): 1652–8PubMedCrossRef

18.

Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 2004; 44(6): 559–69PubMedCrossRef

19.

Van Roon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005; 28(12): 1131–9PubMedCrossRef

20.

Klungel OH, de Boer A, Paes AH, et al. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 1999; 21(5): 217–20PubMedCrossRef

21.

Monster TB, Janssen WM, de Jong PE, et al. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002; 11(5): 379–84PubMedCrossRef

22.

van Mil JW, Dudok van Heel MC, Boersma M, et al. Interventions and documentation for drug-related problems in Dutch community pharmacies. Am J Health Syst Pharm 2001; 58(15): 1428–31PubMed

23.

Knapp KK, Katzman H, Hambright JS, et al. Community pharmacist interventions in a capitated pharmacy benefit contract. Am J Health Syst Pharm 1998; 55(11): 1141–5PubMed

24.

Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69(4): 260–5PubMedCrossRef

25.

Merlo J, Liedholm H, Lindblad U, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 2001; 323(7310): 427–8PubMedCrossRef

26.

Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21(3): 153–8PubMedCrossRef

27.

Peng CC, Glassman PA, Marks IR, et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 2003; 9(6): 513–22PubMed

28.

Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28(1): 67–80PubMedCrossRef

29.

Bergk V, Gasse C, Rothenbacher D, et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76(1): 85–96PubMedCrossRef

30.

Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003; 59(8-9): 689–95PubMedCrossRef

31.

Viktil KK, Blix HS, Reikvam A, et al. Comparison of drug-related problems in different patient groups. Ann Pharmacother 2004; 38(6): 942–8PubMedCrossRef

32.

Roughead EE, Barratt JD, Gilbert AL. Medication-related problems commonly occurring in an Australian community setting. Pharmacoepidemiol Drug Saf 2004; 13(2): 83–7PubMedCrossRef

33.

Weingart SN, Toth M, Sands DZ, et al. Physicians’ decisions to override computerized drug alerts in primary care. Arch Intern Med 2003; 163(21): 2625–31PubMedCrossRef

34.

De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004; 76(1): 1–17PubMedCrossRef

35.

Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (Wash DC) 2004; 44(2): 136–41CrossRef

36.

Becker ML, Kallewaard M, Caspers PW, et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 2005; 28(5): 371–8PubMedCrossRef

Title: Clinical Risk Management in Dutch Community Pharmacies
The Case of Drug-Drug Interactions
Authors: Henk Buurma
Peter A.G.M De Smet
Antoine C.G. Egberts
Publication date: 01-08-2006
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 8/2006
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200629080-00009

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Risk Management in Dutch Community Pharmacies

The Case of Drug-Drug Interactions

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2006

Drug-Induced Thrombocytopenia

An Industry Perspective on the Erice Declaration and Risk Minimisation Plans

Can Decisional Algorithms Replace Global Introspection in the Individual Causality Assessment of Spontaneously Reported ADRs?

Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma

Case Reports and Drug Safety

Long-Acting β2-Agonists in Asthma